CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

Data Compilation
#PharmaFlow

Pipeline Prospector September 2025: Genmab buys Merus for ~US$ 8 billion, Pfizer buys Metsera to enter obesity race

Stock Recap
#PipelineProspector

Methotrexate, Disodium Salt

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

54 API Suppliers, 22 USDMF, 8 CEP/COS, 4 JDMF, 3 EU WC, 10 NDC API, 30 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

169 Drugs in Development

169 Drugs in Development

INTERMEDIATES

7 Intermediate Suppliers

7 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

859 FDF Dossiers, 128 FDA Orange Book, 545 Europe, 59 Canada, 59 Australia, 13 South Africa, 55 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 100MG BASE/VIAL, INJECTABLE;INJECTION - EQ 1GM BASE/VIAL, INJECTABLE;INJECTION - EQ 1GM BASE/40ML (EQ 25MG BASE/ML), INJECTABLE;INJECTION - EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML), INJECTABLE;INJECTION - EQ 2.5MG BASE/ML, INJECTABLE;INJECTION - EQ 20MG BASE/VIAL, INJECTABLE;INJECTION - EQ 20MG BASE/2ML (EQ 10MG BASE/ML), INJECTABLE;INJECTION - EQ 25MG BASE/ML, INJECTABLE;INJECTION - EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 50MG BASE/VIAL, INJECTABLE;INJECTION - EQ 50MG BASE/2ML (EQ 25MG BASE/ML), SOLUTION;SUBCUTANEOUS - 10MG/0.4ML (10MG/0.4ML), SOLUTION;SUBCUTANEOUS - 12.5MG/0.5ML (12.5MG/0.5ML), SOLUTION;SUBCUTANEOUS - 15MG/0.6ML (15MG/0.6ML), SOLUTION;SUBCUTANEOUS - 17.5MG/0.7ML (17.5MG/0.7ML), SOLUTION;SUBCUTANEOUS - 20MG/0.8ML (20MG/0.8ML), SOLUTION;SUBCUTANEOUS - 22.5MG/ML (22.5MG/ML), SOLUTION;SUBCUTANEOUS - 25MG/1ML (25MG/1ML), SOLUTION;SUBCUTANEOUS - 7.5MG/0.3ML (7.5MG/0.3ML), TABLET;ORAL - EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc, 4 SPI Pharma, 5 DKSH, 1 Pharm-RX Chemical, 5 Gangwal Healthcare, 5 Nanjing Well Pharmaceutical, 4 Kirsch Pharma, 1 ACG Worldwide, 9 Actylis, 1 Aeon Procare, 6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 17 BASF, 1 Bioplus Life Sciences, 1 CD Formulation, 1 Clariant, 10 Corel Pharma Chem, 6 DFE Pharma, 1 Esteem Industries, 3 Finar, 9 Gangwal Chemicals, 4 Ideal Cures, 3 Ingredion Pharma Solutions, 24 Kerry, 2 Keval Exports, 3 Kima Chemical, 6 Lonza Capsugel, 11 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 1 Novo Excipients, 2 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Qualicaps, 17 Roquette, 13 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 10 Sigachi Industries, 3 Silverline Chemicals, 2 The Dow Chemical Company, 1 Valens Pharmachem, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

42 Coating Systems & Additives, 41 Fillers, Diluents & Binders, 27 Direct Compression, 24 Granulation, 24 Thickeners and Stabilizers, 20 Controlled & Modified Release, 18 Solubilizers, 18 Topical, 17 Disintegrants & Superdisintegrants, 16 Parenteral, 15 Lubricants & Glidants, 12 Taste Masking, 11 Film Formers & Plasticizers, 11 Co-Processed Excipients, 8 Emulsifying Agents, 8 Chewable & Orodispersible Aids, 6 Rheology Modifiers, 5 Surfactant & Foaming Agents, 5 API Stability Enhancers, 5 Empty Capsules, 4 Vegetarian Capsules, 4 Coloring Agents

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 129 News #PharmaBuzz

GLOBAL SALES INFORMATION

26 US Medicaid Prescriptions, 155 Regulatory FDF Prices

MARKET PLACE

23 APIs, 23 FDF Dossiers

PATENTS & EXCLUSIVITIES

144 US Patents

144 US Patents

REF. STANDARDS & IMPURITIES

6 EDQM, 4 JP, 2 Others

$ Xls download

Filters

Last Updated on PharmaCompass	Virtual Booth	Country	Holder	DMF No.	Subject	Submission Date	Status	Type	GDUFA DMF Review	GDUFA Review Date	GDUFA Payment Date
27/09/2025	Fermion Oy	Finland	FERMION OY	4246	METHOTREXATE	1981-08-06	Active	II	Complete	2013-06-08	2013-05-23
27/09/2025	Pfanstiehl	U.S.A	PFANSTIEHL INC	39988	METHOTREXATE, HIGH PURITY LOW ENDOTOXIN, LOW METALS, USP, EP, BP, JP, ChP (M-166-1)	2024-06-05	Active	II	N/A

Methotrexate, Disodium Salt

Methotrexate, Disodium Salt

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

54 API Suppliers

22 USDMF

8 CEP/COS

4 JDMF

3 EU WC

10 NDC API

30 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

169 Drugs in Development

INTERMEDIATES

7 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

859 FDF Dossiers

128 FDA Orange Book

545 Europe

59 Canada

59 Australia

13 South Africa

55 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 100MG BASE/VIAL

INJECTABLE;INJECTION - EQ 1GM BASE/VIAL

INJECTABLE;INJECTION - EQ 1GM BASE/40ML (EQ 25MG BASE/ML)

INJECTABLE;INJECTION - EQ 2.5GM BASE/100ML (EQ 25MG BASE/ML)

INJECTABLE;INJECTION - EQ 2.5MG BASE/ML

INJECTABLE;INJECTION - EQ 20MG BASE/VIAL

INJECTABLE;INJECTION - EQ 20MG BASE/2ML (EQ 10MG BASE/ML)

INJECTABLE;INJECTION - EQ 25MG BASE/ML

INJECTABLE;INJECTION - EQ 500MG BASE/20ML (EQ 25MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 50MG BASE/VIAL

INJECTABLE;INJECTION - EQ 50MG BASE/2ML (EQ 25MG BASE/ML)

SOLUTION;SUBCUTANEOUS - 10MG/0.4ML (10MG/0.4ML)

SOLUTION;SUBCUTANEOUS - 12.5MG/0.5ML (12.5MG/0.5ML)

SOLUTION;SUBCUTANEOUS - 15MG/0.6ML (15MG/0.6ML)

SOLUTION;SUBCUTANEOUS - 17.5MG/0.7ML (17.5MG/0.7ML)

SOLUTION;SUBCUTANEOUS - 20MG/0.8ML (20MG/0.8ML)

SOLUTION;SUBCUTANEOUS - 22.5MG/ML (22.5MG/ML)

SOLUTION;SUBCUTANEOUS - 25MG/1ML (25MG/1ML)

SOLUTION;SUBCUTANEOUS - 7.5MG/0.3ML (7.5MG/0.3ML)

TABLET;ORAL - EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Rochem International Inc

4 SPI Pharma

5 DKSH

1 Pharm-RX Chemical

5 Gangwal Healthcare

5 Nanjing Well Pharmaceutical

4 Kirsch Pharma

1 ACG Worldwide

9 Actylis

1 Aeon Procare

6 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

17 BASF

1 Bioplus Life Sciences

1 CD Formulation

1 Clariant

10 Corel Pharma Chem

6 DFE Pharma

1 Esteem Industries

3 Finar

9 Gangwal Chemicals

4 Ideal Cures

3 Ingredion Pharma Solutions

24 Kerry

2 Keval Exports

3 Kima Chemical

6 Lonza Capsugel

11 Microlex e.U

1 Nanjing Bold Chemical

2 Nitika Pharmaceutical Specialities

2 Nomisma Healthcare

1 Novo Excipients

INJECTABLE;INJECTION - EQ 500MG BASE/20ML (EQ 25MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 2.5MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons